JPWO2020023486A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023486A5 JPWO2020023486A5 JP2021503736A JP2021503736A JPWO2020023486A5 JP WO2020023486 A5 JPWO2020023486 A5 JP WO2020023486A5 JP 2021503736 A JP2021503736 A JP 2021503736A JP 2021503736 A JP2021503736 A JP 2021503736A JP WO2020023486 A5 JPWO2020023486 A5 JP WO2020023486A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- cough
- patient
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 84
- 206010011224 Cough Diseases 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 78
- 206010013975 Dyspnoeas Diseases 0.000 claims description 70
- 208000000059 Dyspnea Diseases 0.000 claims description 68
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 claims description 59
- 229960000805 nalbuphine Drugs 0.000 claims description 55
- 230000009467 reduction Effects 0.000 claims description 54
- 239000012458 free base Substances 0.000 claims description 28
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 26
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 208000013116 chronic cough Diseases 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 16
- 208000013220 shortness of breath Diseases 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 12
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 9
- 238000004448 titration Methods 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 239000000779 smoke Substances 0.000 claims description 8
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- FLNYCRJBCNNHRH-OIYLJQICSA-N 3-[(3ar,4r,5s,7as)-5-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one Chemical compound C1([C@H]2[C@@H]3CN(C[C@H]3CC[C@@H]2O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2CCC(=O)C=2)=CC=C(F)C=C1 FLNYCRJBCNNHRH-OIYLJQICSA-N 0.000 claims description 4
- HLWURFKMDLAKOD-UHFFFAOYSA-N 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(OC)=CC(C(C)C)=C1OC1=CN=C(N)N=C1N HLWURFKMDLAKOD-UHFFFAOYSA-N 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- 229960000265 cromoglicic acid Drugs 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940121285 gefapixant Drugs 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229960001513 nalbuphine hydrochloride Drugs 0.000 claims description 4
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 4
- 229960004378 nintedanib Drugs 0.000 claims description 4
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 4
- 229960003073 pirfenidone Drugs 0.000 claims description 4
- 229950011343 serlopitant Drugs 0.000 claims description 4
- 229960003433 thalidomide Drugs 0.000 claims description 4
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 206010049119 Emotional distress Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 244000061176 Nicotiana tabacum Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 230000009798 acute exacerbation Effects 0.000 claims description 2
- 238000003915 air pollution Methods 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000000428 dust Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000006397 emotional response Effects 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 239000002085 irritant Substances 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000002756 mu opiate receptor agonist Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000009325 pulmonary function Effects 0.000 claims description 2
- 238000009613 pulmonary function test Methods 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000021317 sensory perception Effects 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 229960004380 tramadol Drugs 0.000 claims description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 238000011976 chest X-ray Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 1
- -1 smoking Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024124443A JP2024153828A (ja) | 2018-07-23 | 2024-07-31 | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701902P | 2018-07-23 | 2018-07-23 | |
| US62/701,902 | 2018-07-23 | ||
| PCT/US2019/042994 WO2020023486A1 (en) | 2018-07-23 | 2019-07-23 | Treatment of chronic cough, breathlessness and dyspnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124443A Division JP2024153828A (ja) | 2018-07-23 | 2024-07-31 | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531299A JP2021531299A (ja) | 2021-11-18 |
| JP2021531299A5 JP2021531299A5 (https=) | 2022-07-29 |
| JPWO2020023486A5 true JPWO2020023486A5 (https=) | 2022-07-29 |
Family
ID=69162461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503736A Pending JP2021531299A (ja) | 2018-07-23 | 2019-07-23 | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
| JP2024124443A Pending JP2024153828A (ja) | 2018-07-23 | 2024-07-31 | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124443A Pending JP2024153828A (ja) | 2018-07-23 | 2024-07-31 | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20200022974A1 (https=) |
| EP (1) | EP3826635A4 (https=) |
| JP (2) | JP2021531299A (https=) |
| KR (1) | KR20210035854A (https=) |
| CN (5) | CN112703000B (https=) |
| AU (2) | AU2019309913B2 (https=) |
| BR (2) | BR112021001177A2 (https=) |
| CA (1) | CA3106995A1 (https=) |
| IL (2) | IL318587A (https=) |
| MX (2) | MX2021000908A (https=) |
| SG (1) | SG11202100580UA (https=) |
| WO (1) | WO2020023486A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021531299A (ja) | 2018-07-23 | 2021-11-18 | トレビ セラピューティクス インコーポレイテッド | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
| KR20220127849A (ko) * | 2020-01-10 | 2022-09-20 | 트레비 테라퓨틱스, 인코포레이티드 | 날부핀의 투여 방법 |
| WO2026025110A1 (en) * | 2024-07-26 | 2026-01-29 | Trevi Therapeutics, Inc. | Treatment of refractory chronic cough |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443442A (en) | 1979-12-21 | 1984-04-17 | Skillern Scott D | Method and composition for treatment of acne vulgaris |
| AU8952282A (en) | 1982-08-25 | 1984-03-29 | Joel E. Bernstein | Method of treating pruritis and composition therefor |
| US4720384A (en) | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
| US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| ES2236630T3 (es) | 1996-11-25 | 2005-07-16 | Toray Industries, Inc. | Agente antipruritico. |
| US6787149B1 (en) | 1996-12-12 | 2004-09-07 | El Khoury And Stein Ltd. | Topical application of opioid analgesic drugs such as morphine |
| US6896899B2 (en) * | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
| US5760023A (en) | 1997-07-14 | 1998-06-02 | Adolor Corporation | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith |
| MXPA99011298A (es) | 1997-07-14 | 2004-10-28 | Adolor Corp | Formulaciones farmaceuticas antiprurito de agonista kappa y metodo para tratar prurito con las mismas. |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| JP2001163784A (ja) | 1999-12-06 | 2001-06-19 | Toray Ind Inc | 角膜または結膜用止痒剤 |
| DE19960154A1 (de) * | 1999-12-14 | 2001-07-12 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie |
| JP4370683B2 (ja) | 2000-05-08 | 2009-11-25 | 東レ株式会社 | そう痒疾患の検査方法 |
| DE10116978A1 (de) | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
| ITMI20010907A1 (it) | 2001-05-02 | 2002-11-02 | Valpharma Sa | Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi |
| US20030054030A1 (en) | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
| ES2654819T3 (es) | 2001-10-18 | 2018-02-15 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opioides |
| US6703398B2 (en) | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| HUE032656T2 (en) | 2002-04-05 | 2017-10-30 | Euro Celtique Sa | Pharmaceutical composition containing oxicodone and naloxone |
| US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| DE10229842A1 (de) | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| ES2392525T3 (es) | 2002-07-15 | 2012-12-11 | F. Hoffmann-La Roche Ag | Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4 |
| SI2263691T1 (sl) | 2002-07-15 | 2012-12-31 | F. Hoffmann-La Roche Ag | Zdravljenje raka z rekombinantnim humaniziranim monoklonskim anti-ErbB2 protitelesom 2C4 (rhuMAb 2C4) |
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| US7459146B2 (en) | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
| DE602004026604D1 (de) | 2003-09-25 | 2010-05-27 | Euro Celtique Sa | Pharmazeutische kombinationen von hydrocodon und naltrexon |
| JP4882744B2 (ja) | 2004-03-30 | 2012-02-22 | 東レ株式会社 | 止痒剤 |
| EP1763349A2 (en) | 2004-06-03 | 2007-03-21 | Jonathan J. Burbaum | Pharmaceutical compositions for the treatment of pruritus |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| ES2462541T3 (es) | 2005-06-09 | 2014-05-23 | Meda Ab | Método y composición para el tratamiento de trastornos inflamatorios |
| US8394812B2 (en) * | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| HUE053838T2 (hu) * | 2005-08-24 | 2021-07-28 | Endo Pharmaceuticals Inc | Nyújtott felszabadulású nabulfin-készítmények |
| JP2009506080A (ja) | 2005-08-30 | 2009-02-12 | クィーンズ ユニバーシティー アット キングストン | 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法 |
| WO2007133816A2 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| JP2008109898A (ja) | 2006-10-31 | 2008-05-15 | Toray Ind Inc | 鎮痒作用を有する化合物のスクリーニング方法 |
| MX2009005000A (es) | 2006-11-10 | 2009-10-12 | Cara Therapeutics Inc | Amidas de peptidos sinteticos. |
| AU2007352557A1 (en) | 2006-11-22 | 2008-11-13 | Progenics Pharmaceuticals, Inc. | (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
| US20080176884A1 (en) | 2006-11-22 | 2008-07-24 | Progenics Pharmaceuticals, Inc. | 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs |
| EP2099456A2 (en) | 2006-11-22 | 2009-09-16 | Progenics Pharmaceuticals, Inc. | N-oxides of 4,5-epoxy-morphinanium analogs |
| US20080207667A1 (en) * | 2007-02-23 | 2008-08-28 | Rhame Robert W | Use of nalbuphine and related compounds to treat symptoms of respiratory problems |
| CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
| CN101677997B (zh) | 2007-03-30 | 2012-05-09 | 泰奥加制药公司 | 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂 |
| WO2008129000A1 (en) | 2007-04-20 | 2008-10-30 | Novartis Ag | Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders |
| ES2396600T3 (es) | 2007-04-23 | 2013-02-22 | Symrise Ag | Ésteres de polietilenglicol y preparaciones cosméticas y/o dermatológicas |
| WO2009000878A1 (en) | 2007-06-28 | 2008-12-31 | Novartis Ag | Kallikrein 7 modulators |
| EP2197427A2 (en) | 2007-09-04 | 2010-06-23 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
| US20090093509A1 (en) | 2007-10-08 | 2009-04-09 | Tahir Nazir | Methods and Compositions for the Treatment of Pruritus |
| US20110112129A2 (en) | 2007-11-26 | 2011-05-12 | Pharmacofore, Inc. | Peripheral Phenolic Opioid Antagonist |
| WO2009103004A1 (en) | 2008-02-14 | 2009-08-20 | Alkermes, Inc. | Selective opioid compounds |
| US8686040B2 (en) | 2008-03-31 | 2014-04-01 | Rdd Pharma Ltd. | Method for treating anal pruritis and other perianal disorders |
| WO2009132313A2 (en) | 2008-04-25 | 2009-10-29 | Progenics Pharmaceuticals, Inc. | Morphinan derivatives of organic and inorganic acids |
| US20110262446A1 (en) * | 2008-10-14 | 2011-10-27 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
| EA201101207A1 (ru) | 2009-02-24 | 2012-04-30 | Новартис Аг | Применение антагонистов рецептора nk |
| US20100227876A1 (en) | 2009-03-06 | 2010-09-09 | Rechfensen Llp | Methods of Reducing Side Effects of Analgesics |
| EP3170395A1 (en) | 2009-03-19 | 2017-05-24 | Alkermes Pharma Ireland Limited | Morphinan derivatives with high oral bioavailability |
| AU2010238925A1 (en) | 2009-04-22 | 2011-12-15 | Phoeme Gmbh | Particulate pharmaceutical composition having an opioid and an opioid antagonist |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| US9364623B2 (en) * | 2009-07-15 | 2016-06-14 | UNIVERSITé LAVAL | Method and device for administering oxygen to a patient and monitoring the patient |
| AU2011211223B2 (en) | 2010-01-29 | 2014-10-23 | Toray Industries, Inc. | Therapeutic or prophylactic agent for biliary diseases |
| IT1398930B1 (it) | 2010-03-24 | 2013-03-28 | Molteni & C | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. |
| FR2963889B1 (fr) * | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
| JP2012087101A (ja) | 2010-10-21 | 2012-05-10 | Holger Hermann Lars | オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物 |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| ES2984559T3 (es) | 2012-12-14 | 2024-10-29 | Trevi Therapeutics Inc | Métodos de tratamiento del prurito |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| RU2650118C2 (ru) * | 2013-08-23 | 2018-04-09 | Афферент Фармасьютикалз Инк. | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться |
| MX2016016404A (es) | 2014-06-13 | 2017-11-30 | Trevi Therapeutics Inc | Metodos para el tratamiento del prurito. |
| WO2017108917A1 (en) * | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| CA3008920C (en) * | 2015-12-23 | 2024-09-17 | Conrig Pharma Aps | SUPLATAST TOSILATE FOR THE TREATMENT OF COUGH ASSOCIATED WITH INTERSTITIAL LUNG DISEASE |
| WO2017120468A1 (en) | 2016-01-06 | 2017-07-13 | Trevi Therapeutics, Inc. | Therapeutic use of nalbuphine without aquaretic effects |
| RS59313B1 (sr) * | 2016-01-08 | 2019-10-31 | Nerre Therapeutics Ltd | Orvepitant za lečenje hroničnog kašlja |
| CN105560202B (zh) | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
| CN109310656A (zh) | 2016-03-21 | 2019-02-05 | 特雷维治疗股份有限公司 | 尿毒症性瘙痒症的治疗 |
| CN109475626A (zh) * | 2016-07-14 | 2019-03-15 | 儿童医院医疗中心 | 治疗纤维化的方法 |
| EP3506893A4 (en) * | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS |
| MX2019004804A (es) | 2016-10-25 | 2019-08-22 | Trevi Therapeutics Inc | Tratamiento para el prurigo nodula. |
| AU2019301134A1 (en) | 2018-07-11 | 2021-01-21 | Trevi Therapeutics, Inc. | Treatment of the pruritic symptoms of liver disease |
| JP2021531299A (ja) | 2018-07-23 | 2021-11-18 | トレビ セラピューティクス インコーポレイテッド | 慢性咳嗽、息切れ、及び呼吸困難の治療 |
-
2019
- 2019-07-23 JP JP2021503736A patent/JP2021531299A/ja active Pending
- 2019-07-23 MX MX2021000908A patent/MX2021000908A/es unknown
- 2019-07-23 CN CN201980060423.3A patent/CN112703000B/zh active Active
- 2019-07-23 SG SG11202100580UA patent/SG11202100580UA/en unknown
- 2019-07-23 BR BR112021001177-3A patent/BR112021001177A2/pt unknown
- 2019-07-23 KR KR1020217005208A patent/KR20210035854A/ko not_active Ceased
- 2019-07-23 WO PCT/US2019/042994 patent/WO2020023486A1/en not_active Ceased
- 2019-07-23 EP EP19840931.0A patent/EP3826635A4/en active Pending
- 2019-07-23 CA CA3106995A patent/CA3106995A1/en active Pending
- 2019-07-23 CN CN202410607853.5A patent/CN118512453A/zh active Pending
- 2019-07-23 BR BR122023024228-9A patent/BR122023024228A2/pt unknown
- 2019-07-23 IL IL318587A patent/IL318587A/en unknown
- 2019-07-23 AU AU2019309913A patent/AU2019309913B2/en active Active
- 2019-07-23 CN CN202410607851.6A patent/CN118512452A/zh active Pending
- 2019-07-23 CN CN202410600839.2A patent/CN118512451A/zh active Pending
- 2019-07-23 IL IL280301A patent/IL280301B2/en unknown
- 2019-07-23 US US16/519,831 patent/US20200022974A1/en not_active Abandoned
- 2019-07-23 CN CN202410600859.XA patent/CN118477079A/zh active Pending
-
2021
- 2021-01-22 MX MX2024009649A patent/MX2024009649A/es unknown
-
2022
- 2022-01-14 US US17/576,208 patent/US20220409613A1/en not_active Abandoned
- 2022-03-24 US US17/702,995 patent/US11660296B2/en active Active
-
2024
- 2024-07-31 JP JP2024124443A patent/JP2024153828A/ja active Pending
- 2024-09-04 US US18/824,121 patent/US20240423975A1/en active Pending
-
2025
- 2025-05-21 AU AU2025203754A patent/AU2025203754A1/en active Pending
- 2025-07-16 US US19/270,674 patent/US20250339424A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518122A5 (https=) | ||
| Gupta et al. | Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing | |
| Singh | Small airway disease in patients with chronic obstructive pulmonary disease | |
| AU2016202597B2 (en) | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration | |
| RU2003131178A (ru) | Агонисты никотиновых рецепторов для лечения воспалительных заболеваний | |
| WO2010107404A1 (en) | Stable pharmaceutical combinations | |
| CN112741835A (zh) | 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 | |
| JP2022517788A (ja) | Ｐｄｅ－５阻害剤と吸入用一酸化窒素との併用薬物療法 | |
| CN112055593A (zh) | 包含(2s)-n-{(1s)-1-氰基-2-[4-(3-甲基-2-氧代-2,3-二氢-1,3-苯并噁唑-5-基)苯基]乙基}-1,4-氧杂氮杂环庚烷-2-甲酰胺的药物组合物 | |
| JP2007314517A (ja) | ロキソプロフェンを含有する鎮咳又は去痰のための医薬組成物 | |
| JP2021531299A5 (https=) | ||
| JP6145946B2 (ja) | 併用ａｌｓ療法 | |
| ZA200707930B (en) | Roflumilast for the treatment of pulmonary hypertension | |
| JP2024153828A (ja) | 慢性咳嗽、息切れ、及び呼吸困難の治療 | |
| CN108366981B (zh) | 用于治疗与间质性肺病相关的咳嗽的甲磺司特 | |
| JPWO2020023486A5 (https=) | ||
| JP2013510187A (ja) | 誘発されたジスキネジアを治療又は予防するためのキセノンベースの吸入可能薬物 | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| RU2021104447A (ru) | Лечение хронического кашля, одышки и диспноэ | |
| CN116033900A (zh) | 治疗冠状病毒暴露所致疾病的方法 | |
| JP2017513866A (ja) | パーキンソン病の運動症状変動の迅速な緩和 | |
| Sorbera et al. | Roflumilast | |
| AU2003288169B2 (en) | Synergistic combination comprising roflumilast and (R,R) -formoterol | |
| JP2019108379A (ja) | パーキンソン病の運動症状変動の迅速な緩和 | |
| US20060111443A1 (en) | Preventive therapeutic composition for muscular fatigue, pulled muscle and disease attributed thereto |